Efficacy and safety of generic voriconazole for treatment of invasive fungal infections

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

TCTR

Registry ID

TCTR20180111001

Enrollment

Registered

2018-01-11

Start date

2018-04-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hematological aptients Immunocomprimsed patients Transplant recipients invasive aspergillosis fungal infection voriconazole

Interventions

Local voriconazole will be prescribed to patients diagnosed invasive fungal diseases.

Active Comparator Drug

Local voriconazole

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients 18 years of age or older who diagnosed invasive fungal infection

Exclusion criteria

Exclusion criteria: History of voriconazole allergy Received medication that have significant interactions with voriconazole

Design outcomes

Primary

Measure	Time frame
Global response 12 weeks Satisfactory global response (decreased of lesion by 50% at week 12 with clinical improve	—

Secondary

Measure	Time frame
Mortality week 4 and week 12 Dead rate,Safety first 12 weeks Adverse drug reactions	—

Countries

Thailand

Contacts

Public ContactMethee Chayakulkeeree

Faculty of Medicine Siriraj Hospital

methee.cha@mahidol.ac.th+6624199462

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026